Community Series in Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer, Colon Cancer and Esophageal Cancer, volume II

97.1K

views

177

authors

19

articles

Editorial

03 July 2023

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II

Yueyi Li

,

Yusha Wang

,

Jinsheng Gao

,

Keqin Tan

, 3 more and

Xuelei Ma

1,882 views

0 citations

Editors

4

Sichuan University

Department of Radiation Oncology, University Hospital Erlangen

University Hospital Erlangen

Sichuan University

Impact

About

This Research Topic is the second volume of the 'Community Series in Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer, Colon Cancer and Esophageal Cancer'. Please see the first volume here.

Rapid progress has been made in the development of immune checkpoint inhibitors (ICIs) as an effective treatment for non-small cell lung cancer (NSCLC), colon cancer and esophageal cancer. ICIs targeting programmed cell death-1 (PD-1) and PD-L1, such as Nivolumab, Atezolizumab, and Pembrolizumab, have been used in the first line treatment for advanced NSCLC, either as monotherapy, or in combination with other immunotherapy drugs or chemotherapy. The five-year survival rate of patients treated with ICIs varies from person to person and also depends on the subtypes of tumor. For example, ICIs have proved to be quite effective in treatment of mismatch repair deficient and microsatellite instability high colon tumors, but it has either been unsuccessful when used in other subtypes, or not extensively explored.

The efficacy of ICIs is limited by resistance which is associated with immune metabolic dysregulation. About 70 % of patients are classified as non-responders to ICIs, or they progress after initial response to these ICIs. Immunotherapy resistance is due to a combination of factors, such as immune escape, the decrease of anti-tumor T lymphocytes and increased extracellular adenosine. In addition, immune-tolerant tumor microenvironment caused by immunotherapy may lead to immune-related adverse events, affecting several organs or systems and even leading to termination of treatment.

At a result, the factors for ICIs immunotherapy that can predict the response or resistance of cancer patients is very important. For NSCLC and colon cancer, PD-L1 expression by immunohistochemistry is now recognized as an effective biomarker to predict the appreciate response to ICIs. But some patients with highly positive PD-L1 do not show response. PD-1 expression is still unperfect to establish effective treatment strategies. Better and more predictive factors are needed for more accurate patient selection for ICI treatment in NSCLC, colon cancer and esophageal cancer.

This Research Topic aims to provide a forum to update and discuss the new discoveries in the field of immunotherapy with immune checkpoint inhibitors in non-small cell lung cancer, colon cancer and esophageal cancer.

We welcome submissions of Original Research, Review, and Mini Review articles focusing on major trends and challenges in this field, including but not limited to:

? Novel findings on the mechanisms underlying resistance to ICIs (eg. impaired HLA Class I Antigen processing)
? New preclinical or clinical studies on the combination of ICIs in treatment of cancers
? Discovery and validation of new biomarkers to predict the therapeutic efficacy of PD-1 (eg. the application of antigenicity, regulatory molecules on cancer or cancer steam cells in the treatment of colon cancer)
? The changes in the tumor microenvironment and their impact on patients’ response to immunotherapy with ICIs (eg. increase of tumor-infiltrating immune cells is often described as being capable of turning immunologically “cold” tumors into “hot” ones)

This Research Topic is the second volume of the 'Community Series in Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer, Colon Cancer and Esophageal Cancer'. Please see the first volume here.

Rapid progress has been made in the development of immune checkpoint inhibitors (ICIs) as an effective treatment for non-small cell lung cancer (NSCLC), colon cancer and esophageal cancer. ICIs targeting programmed cell death-1 (PD-1) and PD-L1, such as Nivolumab, Atezolizumab, and Pembrolizumab, have been used in the first line treatment for advanced NSCLC, either as monotherapy, or in combination with other immunotherapy drugs or chemotherapy. The five-year survival rate of patients treated with ICIs varies from person to person and also depends on the subtypes of tumor. For example, ICIs have proved to be quite effective in treatment of mismatch repair deficient and microsatellite instability high colon tumors, but it has either been unsuccessful when used in other subtypes, or not extensively explored.

The efficacy of ICIs is limited by resistance which is associated with immune metabolic dysregulation. About 70 % of patients are classified as non-responders to ICIs, or they progress after initial response to these ICIs. Immunotherapy resistance is due to a combination of factors, such as immune escape, the decrease of anti-tumor T lymphocytes and increased extracellular adenosine. In addition, immune-tolerant tumor microenvironment caused by immunotherapy may lead to immune-related adverse events, affecting several organs or systems and even leading to termination of treatment.

At a result, the factors for ICIs immunotherapy that can predict the response or resistance of cancer patients is very important. For NSCLC and colon cancer, PD-L1 expression by immunohistochemistry is now recognized as an effective biomarker to predict the appreciate response to ICIs. But some patients with highly positive PD-L1 do not show response. PD-1 expression is still unperfect to establish effective treatment strategies. Better and more predictive factors are needed for more accurate patient selection for ICI treatment in NSCLC, colon cancer and esophageal cancer.

This Research Topic aims to provide a forum to update and discuss the new discoveries in the field of immunotherapy with immune checkpoint inhibitors in non-small cell lung cancer, colon cancer and esophageal cancer.

We welcome submissions of Original Research, Review, and Mini Review articles focusing on major trends and challenges in this field, including but not limited to:

? Novel findings on the mechanisms underlying resistance to ICIs (eg. impaired HLA Class I Antigen processing)
? New preclinical or clinical studies on the combination of ICIs in treatment of cancers
? Discovery and validation of new biomarkers to predict the therapeutic efficacy of PD-1 (eg. the application of antigenicity, regulatory molecules on cancer or cancer steam cells in the treatment of colon cancer)
? The changes in the tumor microenvironment and their impact on patients’ response to immunotherapy with ICIs (eg. increase of tumor-infiltrating immune cells is often described as being capable of turning immunologically “cold” tumors into “hot” ones)

Download ebook

Share

Editors

Sichuan University

Department of Radiation Oncology, University Hospital Erlangen

University Hospital Erlangen

Sichuan University

Impact

97,122 Total views

55,787 Article views

40,087 Article downloads

1,248 Topic views

Published In

Journal Thumbnail

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Journal Thumbnail

Frontiers in Oncology

Cancer Immunity and Immunotherapy

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic